Abstract Number: 1318 • 2019 ACR/ARP Annual Meeting
In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms
Background/Purpose: There was a need to ascertain in a clinical trial the comparative efficacy of diacerein, an IL-1 inhibitor, vis-à-vis celecoxib, a COX-2 inhibitor, in…Abstract Number: 1319 • 2019 ACR/ARP Annual Meeting
Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis
Background/Purpose: Background: The development of knee's osteoarthritis after anterior cruciate ligament ACL injury is now widely recognized. The impact of surgical or rehabilitative management on…Abstract Number: 1320 • 2019 ACR/ARP Annual Meeting
Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort
Background/Purpose: We analyzed the association between individual socio-economic status (SES) variables and clinical symptoms (function, pain and quality of life) in patients with symptomatic knee…Abstract Number: 1321 • 2019 ACR/ARP Annual Meeting
What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative
Background/Purpose: 3D femur bone shape measured by statistical shape modelling (SSM) provides a responsive biomarker of knee OA. However it is unclear how the 3…Abstract Number: 1322 • 2019 ACR/ARP Annual Meeting
Evaluation of Intra-articular CNTX-4975 in Subjects with Painful Bilateral Knee Osteoarthritis: Effects on Pain with Walking and Patient Impression of Change in Pain
Background/Purpose: A double-blind, randomized, placebo-controlled trial (TRIUMPH; NCT02558439) with a single 1 mg intra-articular (IA) injection of CNTX-4975 (highly purified trans-capsaicin) into one knee for…Abstract Number: 1323 • 2019 ACR/ARP Annual Meeting
Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma
Background/Purpose: While there is growing evidences for the efficacy of platelet-rich plasma (PRP), there is still no standardized composition. There are 3 major types of…Abstract Number: 1324 • 2019 ACR/ARP Annual Meeting
Visceral Fat Deposition Associated with Pain in Osteoarthritis
Background/Purpose: Animal model studies have demonstrated the significant role of inflammation in the pathogenesis of osteoarthritis (OA) and of pain. Visceral fat, rather than subcutaneous…Abstract Number: 1325 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA
Background/Purpose: The disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS-5) is a key enzyme in OA (Verma P, et al. J Cell Biochem 2011;112:3507-14). In preclinical models…Abstract Number: 1326 • 2019 ACR/ARP Annual Meeting
Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Background/Purpose: Recent concerns over osteoarthritis (OA) pharmacotherapy safety have led to revision of treatment guidelines and highlight the need for therapies with good safety profiles.…Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…Abstract Number: 1328 • 2019 ACR/ARP Annual Meeting
The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis
Background/Purpose: Previous studies have shown that it is possible to taper DMARDs in RA patients with an inactive disease, but this is accompanied with a…Abstract Number: 1329 • 2019 ACR/ARP Annual Meeting
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Background/Purpose: Filgotinib (FIL) is an orally administered, selective inhibitor of Janus Kinase 1 (JAK1) that is under development for the treatment of RA and other…Abstract Number: 1330 • 2019 ACR/ARP Annual Meeting
No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years
Background/Purpose: Due to demographic changes an increasing number of persons reach an age above 70 years. Therefore, the adequate therapy of elderly patients with rheumatoid…Abstract Number: 1331 • 2019 ACR/ARP Annual Meeting
No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab
Background/Purpose: Spontaneous reports of nine facial paralyses and five facial pareses made by healthcare professionals from Europe have recently prompted EMA’s Pharmacovigilance Risk Assessment Committee…Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
ACR Meeting Abstracts